VIRGINIA RETIREMENT SYSTEMS ET Al Reduces Stock Position in Lantheus Holdings, Inc. $LNTH

VIRGINIA RETIREMENT SYSTEMS ET Al cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 36.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 14,133 shares of the medical equipment provider’s stock after selling 8,000 shares during the quarter. VIRGINIA RETIREMENT SYSTEMS ET Al’s holdings in Lantheus were worth $725,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Harbor Capital Advisors Inc. grew its position in Lantheus by 24.7% during the second quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock worth $15,554,000 after buying an additional 37,691 shares in the last quarter. Reinhart Partners LLC. grew its stake in Lantheus by 16.4% in the 2nd quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock worth $114,905,000 after buying an additional 197,719 shares in the last quarter. Swedbank AB increased its holdings in shares of Lantheus by 11.0% in the 1st quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after buying an additional 121,500 shares during the last quarter. Strs Ohio purchased a new stake in shares of Lantheus during the 1st quarter valued at $4,529,000. Finally, Select Equity Group L.P. grew its position in Lantheus by 899.2% in the first quarter. Select Equity Group L.P. now owns 100,843 shares of the medical equipment provider’s stock worth $9,842,000 after acquiring an additional 90,751 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Ratings Changes

A number of research firms have weighed in on LNTH. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Truist Financial increased their price objective on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings lowered Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Saturday, October 25th. B. Riley reduced their price target on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research report on Tuesday, September 16th. Finally, TD Cowen cut their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, September 15th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $78.00.

Lantheus Price Performance

LNTH stock opened at $67.27 on Monday. The stock has a market capitalization of $4.46 billion, a price-to-earnings ratio of 28.26 and a beta of -0.11. The firm’s 50-day moving average price is $59.97 and its two-hundred day moving average price is $61.69. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $111.29.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $92.51 million for the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%. As a group, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.